Identification of KRas fragment binders using the PhABit platform has demonstrated its utility as a screening approach for challenging protein targets. Rapid follow-up studies by LC-MS/MS enabled straightforward identification of the site of binding, which was consistent with previously reported crystallographic studies. Additionally, hits provided immediate access to an assay to profile published compounds, which could prove useful for further KRas inhibitor development studies.